This article reports on Nano-X Imaging Ltd.'s own public disclosures and press coverage; it is not investment advice, and GSN did not independently verify claims made by the company beyond the linked source.
Nanox.AI, the artificial intelligence subsidiary of Nano-X Imaging Ltd. (Nasdaq: NNOX), presented new clinical study data at the Society of Cardiovascular Computed Tomography’s (SCCT) 2026 annual meeting, held July 11-12, 2026, according to the announcement. The Israel-based, Nasdaq-listed company said two abstracts were presented at the conference, both involving researchers from Brigham and Women’s Hospital and partner institutions, covering the company’s AI technology for detecting incidental coronary artery calcium.
Nano-X Imaging describes its mission, in the company’s own boilerplate language, as driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform that combines imaging hardware, AI software, cloud tools, remote radiology access and health IT services. Nanox.AI, the subsidiary behind the coronary calcium technology, describes itself as the company’s deep-learning medical imaging analytics arm, built to help clinicians extract actionable insights from medical imaging that might otherwise go unnoticed. According to the company’s own description, this SCCT 2026 data presentation is one small, specific step toward that broader stated goal: using AI to flag incidental coronary artery calcium on CT scans that were never ordered for cardiac evaluation in the first place, rather than requiring a separate preventive screening exam.
According to the announcement, the studies showed that the AI’s assessment of coronary artery calcium had high agreement with expert visual assessment. The underlying technology, HealthCCSng, is FDA-cleared software that the company said detects coronary artery calcium on routine CT scans that were not originally ordered for cardiac evaluation.
The company also pointed to findings from a trial referred to as “AI INFORM,” which it said suggest that AI-detected coronary calcium may help clinicians identify patients who could benefit from preventive lipid-lowering therapy. Nano-X Imaging did not disclose further detail about the AI INFORM findings in the portion of the announcement cited here.
Separately, Nanox.AI sponsored a scientific session on aortic valve calcification at the same SCCT meeting, the company said. That session featured Dr. Ofir Koren of Cedars-Sinai Medical Center.
The disclosures were made public via a GlobeNewswire release dated July 7, 2026, ahead of the conference presentations. GSN has not independently reviewed the underlying study data, the full text of the two abstracts, or the AI INFORM trial materials beyond what the company disclosed in its announcement, and readers seeking the primary clinical findings should consult the original SCCT conference materials or peer-reviewed publication when available.
Nano-X Imaging Ltd. trades on the Nasdaq exchange. This article does not constitute investment advice, and GSN makes no assessment of the company’s business prospects or the clinical significance of the presented data beyond what the company itself has stated.
